Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Intrexon Corp    XON

INTREXON CORP

(XON)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/15/2019 07/16/2019 07/17/2019 07/18/2019 07/19/2019 Date
7.49(c) 7.36(c) 7.58(c) 7.61(c) 7.45(c) Last
686 181 747 830 816 324 784 364 800 602 Volume
-1.96% -1.74% +2.99% +0.40% -2.10% Change
More quotes
Financials (USD)
Sales 2019 105 M
EBIT 2019 -171 M
Net income 2019 -188 M
Debt 2019 62,5 M
Yield 2019 -
Sales 2020 120 M
EBIT 2020 -190 M
Net income 2020 -161 M
Finance 2020 133 M
Yield 2020 -
P/E ratio 2019 -6,07x
P/E ratio 2020 -6,13x
EV / Sales2019 12,1x
EV / Sales2020 8,93x
Capitalization 1 203 M
More Financials
Company
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company... 
More about the company
Surperformance© ratings of Intrexon Corp
Trading Rating : Investor Rating :
More Ratings
Latest news on INTREXON CORP
07/01INTREXON : ActoBio Therapeutics™ Progresses AG019 to Next Stage of a Phase..
PR
06/26INTREXON : Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-30..
PU
06/18INTREXON : and Surterra Wellness Partner in $100mm Deal to Advance Commercial Sc..
PR
06/13INTREXON : Subsidiary Precigen to Present at the JMP Securities Life Sciences Co..
PR
06/12INTREXON CORP : Change in Directors or Principal Officers, Submission of Matters..
AQ
06/03INTREXON : Oxitec Successfully Completes First Field Deployment of 2nd Generatio..
PR
06/03INTREXON : Announces Advances in Non-Browning GreenVenus™ Romaine Lettuce
PR
05/30FIBROCELL SCIENCE : Receives FDA Regenerative Medicine Advanced Therapy Designat..
AQ
05/28INTREXON : to Participate in 2019 BIO International Convention
PR
05/13INTREXON : to Present at the Bank of America Merrill Lynch 2019 Healthcare Confe..
PR
More news
Sector news : Biotechnology & Medical Research - NEC
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/17GILEAD SCIENCES : Chief Scientific Officer John McHutchison to Leave
DJ
07/16As steep patent cliff looms, Shionogi moves to develop its own U.S. sales sta..
RE
07/16GSK's two-drug HIV Dovato treatment meets main goal in study
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
More sector news : Biotechnology & Medical Research - NEC
Chart INTREXON CORP
Duration : Period :
Intrexon Corp Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTREXON CORP
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 9,33  $
Last Close Price 7,45  $
Spread / Highest target 87,9%
Spread / Average Target 25,3%
Spread / Lowest Target -6,04%
EPS Revisions
Managers
NameTitle
Randal J. Kirk Chairman & Chief Executive Officer
Thomas Bostick Chief Operating Officer
Rick L. Sterling CFO & Principal Accounting Officer
Thomas David Reed Chief Scientific Officer
Dean Jonathan Mitchell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INTREXON CORP13.91%1 203
IQVIA HOLDINGS INC34.16%30 740
LONZA GROUP31.57%25 623
CELLTRION, INC.--.--%20 071
INCYTE CORPORATION26.66%17 271
EXACT SCIENCES CORPORATION85.26%14 835